In this month's "Virtual Lecture," Ann Moyer, M.D., Ph.D. describes how Pharmagenomic and therapeutic drug monitoring tools aid medical providers in selecting drugs and doses to maximize efficacy while minimizing toxicity for mental illnesses, including depression.
In this month’s “Virtual Lecture,” Christine Snozek, Ph.D. discusses the opioid epidemic as it relates to pain management along with what changes have been made regarding regulations and laboratory support.
New High-Resolution Targeted Opioid Screen: Superior Sensitivity and Specificity to Evaluate Adherence to Prescribed Opioid Therapy
In this month’s “Hot Topic,” Paul Jannetto, Ph.D., discusses the high-resolution targeted opioid screening test from Mayo Clinic Laboratories, which offers sensitivity and specificity for use in the monitoring and management of patients who are prescribed opioid pain-relieving medication.
In this month’s “Hot Topic,” Paul Jannetto, Ph.D., will highlight Mayo Clinic’s new targeted benzodiazepine assay and discuss the advantages and limitations of various urine-screening assays as well as quantitative confirmatory testing to determine compliance to benzodiazepine therapy.
Ann Moyer, M.D., Ph.D. gives an overview of this new test available through Mayo Clinic Laboratories. She discusses when this testing should be ordered, how this testing improves upon other testing approaches, and what clinical action can be taken due to the results of this testing.
PACE / State of CA / State of FL
This “Phlebotomy” webinar reviews: Having a medical procedure or a lab draw can be fearful for children. Even if it is their first time or they have had a bad past experience, there are ways to make these procedures easier for children.
The drugs available today to treat diseases are powerful agents that work as intended for most people. Yet, in some cases, a particular drug at the standard dose might not work for you or may trigger an unintended side effect.
This "Specialty Testing" webinar will provide an overview of evidence-based applications of pharmacogenomics, share recent advances, and discuss the clinical utility of new panels and single-gene tests.
Pharmacogenomic testing is still limited, despite ample research, the existence of guidelines, and the emerging evidence it can help patients. Ann Moyer, M.D., Ph.D., Co-Director of the Personalized Genomics Laboratory at Mayo Clinic in Rochester, Minnesota, makes a case for pharmacogenomics.
Mayo Clinic offers a different approach compared to traditional pain-management testing because our Pain Clinic Survey only tests for the most common drugs of abuse, primarily those characterized as Tier I in the American Association for Clinical Chemistry's laboratory medicine practice guideline. Testing for less-common drugs is only recommended in high-risk patients or when clinically indicated, which leads to more appropriate test utilization, saving ordering institutions time and money.
Ann Moyer, M.D., Ph.D., discusses the importance of pharmacogenomics testing to limit adverse drug reactions and the new focused pharmacogenomics panel available through Mayo Medical Laboratories.
Paul Jannetto, Ph.D., Director of the Clinical and Forensic Toxicology Laboratory at Mayo Clinic, weighs in on the changing methods and usage patterns of cannabis testing, and further explores its place in the laboratory.
Opioid pain relievers play an important role in management of acute and chronic pain, although there are concerns with opioid misuse, abuse, and diversion. In this “Hot Topic,” Paul Jannetto, Ph.D., discusses how to interpret qualitative and/or quantitative urine opiate tests used to monitor compliance in pain patients.